Table 1 Patient characteristics
Patients | n =198 | |
|---|---|---|
Sex | ||
Male | 105 (53%) | |
Female | 93 (47%) | |
Median age at diagnosis (years) | 65 (range 23–93) | |
Date of diagnosis | 1993–1999 | |
pTNM UICC staging (n=198) | 0: Tis, N0, M0 | 0 (0%) |
pT1: ⩽0.75 mm | Ia: pT1, N0, M0 | 57 (29%) |
pT2: 0.76–1.5 mm | Ib: pT2, N0, M0 | 20 (10%) |
pT3a: 1.51–3.0 mm or level IV | IIa: pT3, N0, M0 | 34 (17%) |
pT3b: 3.01–4.0 mm or level IV | IIb: pT4a, N0, M0 | 10 (5%) |
pT4a: >4.0 mm or level V | IIIa: pT4a/pT4b, N1, M0 | 29 (15%) |
pT4b: Satellite met(s) within 2 cm from tumour | IIIb: any pT, N1/N2, M0 | 13 (6%) |
N1: Lymph node met(s) ⩽3 cm | IV: any pT, any N, M1 | 35 (18%) |
N2a: Lymph node met(s) >3 cm | ||
N2b: In-transit met(s) | ||
N2c: Lymph node met(s) >3 cm and in-transit met(s) | ||
M: Distant met(s) | ||
pTNM AJJC staging (n=139) | 0: Tis, N0, M0 | 0 (0%) |
T1: ⩽1.0 mm | Ia: T1a, N0, M0 | 39 (28%) |
a: without ulceration; b: with ulceration or level IV or V | Ib: T1b, T2a, N0, M0 | 18 (13%) |
T2: 1.01–2.0 mm | IIa: T2b, T3a, N0, M0 | 12 (8%) |
a: without ulceration; b: with ulceration | IIb: T3b, T4a, N0, M0 | 13 (9%) |
T3: 2.01–4.0 mm | IIc: T4b, N0, M0 | 5 (4%) |
a: without ulceration; b: with ulceration | IIIa: T1-4a, N1a/N2a, M0 | 11 (7%) |
T4: >4.0 mm | IIIb: T1-4b, N1a/N2a, N1b/N2b | 18 (13%) |
a: without ulceration; b: with ulceration | T1-4a/b, N2c, M0 | |
N1: One lymph node | IIIc: T1-4b, N1b/N2b/N3, M0 | 5 (4%) |
a: micrometastasis; b: macrometastasis | IV: any T, any N, M1 | 22 (16%) |
N2: 2–3 lymph nodes | ||
a: micrometastasis; b: macrometastasis | ||
c: in-transit met(s)/satellite(s) without metastatic lymph nodes | ||
N3: ⩾4 lymph nodes, satellite(s) and metastatic lymph node(s) | ||
M1: Distant met(s) | ||
Median follow-up time (months) | 59 (range 2–141) |
